SOURCE-LINKED INTELLIGENCE

Microbiome-based diagnostics and therapeutics

CORDIS · observation · Publication date unknown

e bacterial genes level whose baseline levels were predictive of future disease onset. In this ERC-PoC, we propose to prioritize the bacteria found in the ERC-funded project (WP1) and use them within machine learning disease diagnostic models (WP2) that we will then license to diagnostic companies. We further propose to build a microbial biobank of the ERC-identified strains by isolating them from cohort participants, functionally characterizing them with metabolomics and combining them into bacterial consortiums (WP3). As these strains have therapeutic potential, we will license them to probiotic or pharmaceutical companies (WP4). Notably, we already validated this approach in two licensing agreements, one with a Japanese-based company who licensed bacteria that we found for treating Atopic Dermatitis, and another with a U.S. based probiotics company who licensed bacteria that we found for weight loss. If successful, our ERC-PoC may thus result in novel microbiome-based diagnostic and therapeutic products for various disease indications.

Read original source ↗ Open in workspace

recordType

award

status

CLOSED

region

EU

value

150000

unit

EUR